Company / R&D per Share
Viridian Therapeutics, Inc.\DE R&D per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.94
FY2024
5-year range
$2.94 / $4.77
FY2020-FY2024
Trend
-17.6%
vs FY2023
Sector context
#72 of 208
Health Care
What the data says
At $2.94, Viridian Therapeutics, Inc.\DE's r&d per share ranks #72 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 9 years, ranging from $1.03 in FY2018 to $23.54 in FY2017.
Based on SEC 10-K filings.
2.94 in FY2024 with a 5-year CAGR of -29.3%.
Declined from $3.14 to $2.94 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -14.9%
- 5-Year CAGR
- -29.3%
- 10-Year CAGR
- -
Sector benchmark
#72 of 208 in Health CareTop 35% of 208This company $2.94 Sector average $28.82
▼
-89.8% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 17.6% year-over-year.
- Ranks #72 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $2.94 | -17.6% |
| FY2023 | $3.57 | +13.5% |
| FY2022 | $3.14 | -34.1% |
| FY2021 | $4.77 | -40.0% |
| FY2020 | $7.96 | -52.2% |
| FY2019 | $16.66 | +1520.6% |
| FY2018 | $1.03 | -95.6% |
| FY2017 | $23.54 | +21.9% |
| FY2016 | $19.31 | +7190.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026